Fostering dialogue and united actions in the field of rare diseases

The RDAF works towards a timely and predictable value assessment process for orphan drugs. With this aim in mind, the RDAF liaises with experts and policy makers to better consider the specificities of rare diseases in the procedures for the assessment of treatment options. The Working Group was created in 2019 to support the initiatives of the RDAF in this area by discussing relevant topics and defining in a multi-stakeholder approach potential solutions and action steps.